InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,568.58
(
0.02%
)
US TECH 100
19,853.60
(
0.04%
)
Dow Jones
39,321.49
(
-0.14%
)
Brent Oil
85.38
(
-1.31%
)
Bitcoin
56,242.68
(
0.71%
)
Post# of 252519
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

turtlepower

Send PM Follow Ignore
Followers 1
Posts 1114
Boards Moderated 0
Alias Born 04/07/2009

turtlepower

Re: biomaven0 post# 141219

Thursday, 05/03/2012 3:21:50 AM

Thursday, May 03, 2012 3:21:50 AM

Post# of 252519
GILD/PCYC - Some insight from bioworld about the differences between the drugs. http://www.bioworld.com/content/gilead-pushes-cancer-pipeline-enters-phase-iii-pi3k-drug-0

BTW does anyone have an opinion about GILD as an oncology player? There were concerns about Merck being one of the worst oncology pharma's after the Endocyte partnership and what that meant regarding Endocytes' drugs. I'm not aware of any oncology history with GILD. Would the same argument apply here and should investors be bearish about GILD's drug or at least not that bullish?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up